Product Code: RP-ID-10151843 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151843
Market Overview:
Global ELISpot and FluoroSpot Assay Industry Market Research 2030
" The main factors leading to the growth of the ELISpot and FluoroSpot testing market are the growing vaccine research to meet the challenge of resistant strains, the increase in the incidence of chronic diseases worldwide, and the technological innovation of analyzers and testing kits. ELISpot and FluoroSpot under evaluation.
Promote the market growth of ELISpot and FluoroSpot detection. ELISpot is a key way to develop vaccines for many diseases, namely AIDS, tuberculosis, HIV, malaria, cancer and influenza. The ELISpot test is one of the most widely used immunoassays for evaluating vaccines in clinical research. This reputation is mainly based on higher sample sensitivity, statistical readability, and ease of use in large-scale screening tests and personal tests. In fact, the test can be used to evaluate the response of T cells and B cells that produce specific antibodies in vaccines.
Reporting range:
According to the reporting range, FluroSpot and ELISpot are usually used with fluorophore-labeled detection reagents to perform actual analysis of the immune system at the single-cell level. The FluoroSpot assay combines the sensitivity of ELISpot with the ability to simultaneously analyze the secretion of multiple analytes, allowing the study of cell populations with different operating characteristics.
Main market trends:
The test kits with the largest market share in the ELISpot and FluoroSpot Assay market are expected to maintain their leading share due to the high incidence of chronic diseases and the increased use of these products for vaccine development in clinical research. According to the World Health Organization (WHO), major chronic diseases currently account for nearly 60% of all deaths and 43% of the global disease burden. By 2020, its contribution is expected to rise to 73% of all deaths and 60% of global morbidity. In addition, in developing countries, 79% of deaths are caused by chronic diseases. In addition, technological innovations in ELISpot and FluoroSpot test kits and analyzers are also expected to drive market growth. North America dominates the market and is expected to dominate the entire ELISpot and FluoroSpot testing market during the forecast period. This is due to factors such as the increasing prevalence of chronic diseases such as infectious diseases and the elderly population. According to the National Center for Biotechnology Information (NCBI), it is estimated that 45% or about 33 million Americans have been diagnosed with at least one chronic disease, which is expected to further increase the demand for ELISpot and FluoroSpot tests in the United States. .
Competitive landscape-
The ELISpot and FluoroSpot testing markets are moderately competitive with some major players. In terms of market share, few major players currently dominate the market. Some well-known companies are making acquisitions and new product releases with other companies to consolidate their position in the global market.
Major Players
Becton, Dickinson and Company
U-CyTech biosciences
Cellular Technologies Limited (CTL)
Mabtech AB
Abcam"
Related Reports
Proof of Quality & Reliability
